养心康片对心梗后心力衰竭模型兔血管紧张素Ⅱ、醛固酮和心肌病理形态的影响
|
摘要
目的观察养心康片对心梗后心衰模型兔心功能、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)和心肌病理形态的影响。方法应用结扎冠脉的方法建立心梗后心力衰竭兔模型,随机分为模型组和养心康组,并设立空白对照组,每组5只。造模后第3日开始给药,养心康组给予养心康片0.51 g/kg,灌胃每日1次。空白对照组和模型组给予等体积的蒸馏水,共4周。观察养心康片对模型兔心功能、AngⅡ、ALD和心肌病理形态的影响。结果模型组的左室舒张末容积(LVEDV)最高,与养心康组比较,差异有统计学意义(P<0.05);模型组左室射血分数(LVEF)、左室短轴缩短率(LVFS)值最低,与养心康组比较,差异有统计学意义(P<0.01);模型组的AngⅡ、ALD水平最高,与养心康组比较其差异有统计学意义(均P<0.05或P<0.01)。病理结果显示养心康组心肌纤维较模型组排列整齐,部分心肌纤维断裂,细胞间隙较空白对照组增宽,间质有少量炎症细胞浸润,心肌细胞部分水肿,局灶性心肌细胞坏死,较模型组明显改善。结论养心康片可以提高心梗后心衰模型兔的心功能,降低血清的AngⅡ、ALD水平,改善心肌病理结构。
Objective: To obs erve the effect of Yangxinkang Decoction on cardiac function,angiotensin Ⅱ(AngⅡ),aldosterone(ALD) and myocardial pathological morphology in rabbits with heart failure after myocardial infarction. Method: The rabbit model of heart failure was established with ligation of coronary artery. The experimental animals were randomly divided into the model group and Yangxinkang Decoction group,and the the blank control group was established.There were 5 rabbits in each group. The third day after modeling,Yangxinkang Decoction group were given Yangxinkang Decoction 0.51 g/kg,gavage once a day. The blank control group and the model group were given equal volume of distilled water for 4 weeks. The effects of Yangxinkang Decoction on cardiac function,Ang Ⅱ,ALD and myocardial pathological morphology were observed in rabbits. Results: Compared with that of Yangxinkang Decoction group,LVEDV of the model group was the highest,and the difference was statistically significant(P < 0.05);the LVEF and LVFS values of the model group were the lowest,and the difference was statistically significant(P < 0.01);the levels of Ang Ⅱand ALD were the highest in the model group,and the difference was statistically significant(P < 0.01). Pathological results showed that compared with the model group,the myocardial fibers of Yangxinkang Decoction group were neatly arranged;some of the myocardial fibers were ruptured;the cell gap was wider than that of the blank control group;there was a little infiltration of inflammatory cells;there was partial edema of cardiomyocytes,as well as necrosis of focal myocardial cells. All above was significantly improved,compared with the model group. Conclusion: Yangxinkang Decoction can improve the cardiac function of rabbits with heart failure after myocardial infarction,decrease the levels of Ang Ⅱ and ALD in serum and improve the myocardial pathological structure.
Objective: To obs erve the effect of Yangxinkang Decoction on cardiac function,angiotensin Ⅱ(AngⅡ),aldosterone(ALD) and myocardial pathological morphology in rabbits with heart failure after myocardial infarction. Method: The rabbit model of heart failure was established with ligation of coronary artery. The experimental animals were randomly divided into the model group and Yangxinkang Decoction group,and the the blank control group was established.There were 5 rabbits in each group. The third day after modeling,Yangxinkang Decoction group were given Yangxinkang Decoction 0.51 g/kg,gavage once a day. The blank control group and the model group were given equal volume of distilled water for 4 weeks. The effects of Yangxinkang Decoction on cardiac function,Ang Ⅱ,ALD and myocardial pathological morphology were observed in rabbits. Results: Compared with that of Yangxinkang Decoction group,LVEDV of the model group was the highest,and the difference was statistically significant(P < 0.05);the LVEF and LVFS values of the model group were the lowest,and the difference was statistically significant(P < 0.01);the levels of Ang Ⅱand ALD were the highest in the model group,and the difference was statistically significant(P < 0.01). Pathological results showed that compared with the model group,the myocardial fibers of Yangxinkang Decoction group were neatly arranged;some of the myocardial fibers were ruptured;the cell gap was wider than that of the blank control group;there was a little infiltration of inflammatory cells;there was partial edema of cardiomyocytes,as well as necrosis of focal myocardial cells. All above was significantly improved,compared with the model group. Conclusion: Yangxinkang Decoction can improve the cardiac function of rabbits with heart failure after myocardial infarction,decrease the levels of Ang Ⅱ and ALD in serum and improve the myocardial pathological structure.
引文
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[2]Greenberg B.J Treatment of heart failure:state of the art and prospectives[J].J Cardiovasc Pharmacol,2001,38:S59.
[3]中华医学会心血管病学分会.中国部分地区1980、1990、2000年慢性心力衰竭住院病例同顾性调查[J].中华心血管病杂志,2002,30(8):450-454.
[4]Me Murray JJ.Clinical practice.Systolic heart failure[J].N Enl J Med,2010,362:228-238.
[5]Shah AM,Mann DL.In search of new therapeutic targets and strategies for heart failure:recent advances in basic science[J].Lancet,2011(378):704-712.
[6]冼绍祥,杨忠奇,任培华,等.Effect of Yangxinkang Tablets(养心康片)on chronic heart failure:a multi-center randomized double-blind placebo-controlled trial[J].Chinese Journal of Integrative Medicine,2015,24(10):733-742.
[7]Mauric PY,Marjorie B,Stuart MC.Comparison of in vivoand in vitro haemodynamic function in experimental heartfailure:use of echocardiography[J].Cardio Res,1996(31):873.
[8]Mancini D,Lietz K.Selection of cardiac transplantation candidates in 2010[J].Circulation,2010,122(2):173-183.
[9]Roger VL,Go AS,Lloyd-Jones DM,et al.Heart disease and stroke statistics-2012 update:a report from the American Heart Association[J].Circulation,2012,125(1):e2-e220.
[10]孙路路,吕蓉,梁涛,等.心力衰竭患者出院后1年内预后状况及影响因素分析[J].中国循环杂志,2013,28(2):125-128.
[11]Tang CH,Chen TH,Wang CC,et al.Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan[J].Eur J Heart Fail,2013,15(10):1194-1202.
[12]Birner C,Ulucan C,Bratfisch M,et al.Antihypertrophic effects of combined inhibition of the renin-angiotensin system(RAS)and neutral endopeptidase(NEP)in progressive,tachycardia-induced experimental heart failure[J].Naunyn Schmiedebergs Arch Pharmacol,2012,385(11):1117-1125.
[13]Wong J.Is there benefit in dual renin-angiotensin-aldosterone system blockade No,yes and maybe:a guide for the perplexed[J].Diab Vasc Dis Res,2013,10(3):193-201.
[14]马文霞,刘芙蓉,杨丹蓉,等.肾素-血管紧张素-醛固酮系统基因多态性与原发性高血压的研究进展[J].国外医学医学地理分册,2017,38(2):207-210.
[15]Francla P,Uccellini A,Frattari A.Extracelluar matrix remodelling in myocardial hypertrophy and failure;focus on osteopontin[J].Auckland,2009,16(4):195-200.
[16]Matsusaka T,Katori H,Inagami T,et al.Communication between myocytes and fibroblasts incardiac remodeling in angiotensin chimeric mice[J].J Clin Invest,1999,103(10):1451-1458.
[17]Brown NJ,Agirbasti MA,Williams GH,et al.Effect of activation and inhibition of renin-angiotension system on plasma PAF1[J].Hypertension,1998,32(6):965-971.
[18]Chatterjee K.Neurohormonal activation in congestive heart failure and the role of vasopressin[J].Am J Cardiol,2005,95(9A):8B-13B.
[19]任培华,冼绍祥,孙敬河,等.养心康片对慢性心功能不全模型兔心肌细胞超微结构的影响[J].中国中医急症,2012,21(4):550-554.
[20]任培华,冼绍祥,孙敬河,等.养心康对慢性心功能不全兔心室重构的影响[J].中药新药与临床药理,2012,22(1):58-60.
[2]Greenberg B.J Treatment of heart failure:state of the art and prospectives[J].J Cardiovasc Pharmacol,2001,38:S59.
[3]中华医学会心血管病学分会.中国部分地区1980、1990、2000年慢性心力衰竭住院病例同顾性调查[J].中华心血管病杂志,2002,30(8):450-454.
[4]Me Murray JJ.Clinical practice.Systolic heart failure[J].N Enl J Med,2010,362:228-238.
[5]Shah AM,Mann DL.In search of new therapeutic targets and strategies for heart failure:recent advances in basic science[J].Lancet,2011(378):704-712.
[6]冼绍祥,杨忠奇,任培华,等.Effect of Yangxinkang Tablets(养心康片)on chronic heart failure:a multi-center randomized double-blind placebo-controlled trial[J].Chinese Journal of Integrative Medicine,2015,24(10):733-742.
[7]Mauric PY,Marjorie B,Stuart MC.Comparison of in vivoand in vitro haemodynamic function in experimental heartfailure:use of echocardiography[J].Cardio Res,1996(31):873.
[8]Mancini D,Lietz K.Selection of cardiac transplantation candidates in 2010[J].Circulation,2010,122(2):173-183.
[9]Roger VL,Go AS,Lloyd-Jones DM,et al.Heart disease and stroke statistics-2012 update:a report from the American Heart Association[J].Circulation,2012,125(1):e2-e220.
[10]孙路路,吕蓉,梁涛,等.心力衰竭患者出院后1年内预后状况及影响因素分析[J].中国循环杂志,2013,28(2):125-128.
[11]Tang CH,Chen TH,Wang CC,et al.Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan[J].Eur J Heart Fail,2013,15(10):1194-1202.
[12]Birner C,Ulucan C,Bratfisch M,et al.Antihypertrophic effects of combined inhibition of the renin-angiotensin system(RAS)and neutral endopeptidase(NEP)in progressive,tachycardia-induced experimental heart failure[J].Naunyn Schmiedebergs Arch Pharmacol,2012,385(11):1117-1125.
[13]Wong J.Is there benefit in dual renin-angiotensin-aldosterone system blockade No,yes and maybe:a guide for the perplexed[J].Diab Vasc Dis Res,2013,10(3):193-201.
[14]马文霞,刘芙蓉,杨丹蓉,等.肾素-血管紧张素-醛固酮系统基因多态性与原发性高血压的研究进展[J].国外医学医学地理分册,2017,38(2):207-210.
[15]Francla P,Uccellini A,Frattari A.Extracelluar matrix remodelling in myocardial hypertrophy and failure;focus on osteopontin[J].Auckland,2009,16(4):195-200.
[16]Matsusaka T,Katori H,Inagami T,et al.Communication between myocytes and fibroblasts incardiac remodeling in angiotensin chimeric mice[J].J Clin Invest,1999,103(10):1451-1458.
[17]Brown NJ,Agirbasti MA,Williams GH,et al.Effect of activation and inhibition of renin-angiotension system on plasma PAF1[J].Hypertension,1998,32(6):965-971.
[18]Chatterjee K.Neurohormonal activation in congestive heart failure and the role of vasopressin[J].Am J Cardiol,2005,95(9A):8B-13B.
[19]任培华,冼绍祥,孙敬河,等.养心康片对慢性心功能不全模型兔心肌细胞超微结构的影响[J].中国中医急症,2012,21(4):550-554.
[20]任培华,冼绍祥,孙敬河,等.养心康对慢性心功能不全兔心室重构的影响[J].中药新药与临床药理,2012,22(1):58-60.